Researchers believe nocturnal home hemodialysis (NHHD) performed every other night may be superior to NHHD performed 6 or 7 times a week.
Hemodialysis patients with a higher percentage of fat tissue respond better to erythropoiesis-stimulating agents.
Low hemoglobin levels increase the risk of death, sepsis, and cerebrovascular accidents following cardiac surgery.
Doses higher than 70 μg per week were associated with a 77% greater risk of cancer compared with non-use of the agents.
It also was associated with high hemoglobin levels and reduced levels of C-reactive protein.
In 3 trials, the annual cost for preventing 1 patient from being transfused varied from $61,188 to $317,988.
Study reveals a decline in the use of erythropoiesis-stimulating agents and an increase in the use of iron.
Each 0.5 mg/dL increment in phosphorus was associated with a 7% increased risk of anemia.
Ordering process cut the number of epoetin alfa doses by 71% and medication costs by 69%.
In a head-to-head comparison, researchers observed a higher rate of adverse events with iron dextran than iron sucrose or ferric gluconate.
Iron absorbed from oral ferric citrate boosted iron stores and sustained hemoglobin levels.
Patients with higher levels of anti-CMV antibodies have lower number of red blood cells.
CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.
Greater resistance to ESA is associated with an increased risk of death among patients on chronic HD.
Considerable variation in incidence of HAA across hospitals; teaching status and region linked to risk.
Serum hepatitis E virus levels were undetectable in 78% of patients at least 6 months after stopping treatment.
Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.
Platelets may aggregate more easily in iron-deficient patients.
Soluble ferric pyrophosphate (Triferic), an investigational drug, is delivered to hemodialysis patients via dialysate.
Geriatric patients with CKD are at high risk for morbidity and mortality from the potential side effects of treatments.
In a study, ferumoxytol and iron sucrose treatment was associated with comparable increases in hemoglobin levels and adverse event rates.
This trait in African-American hemodialysis patients was associated with a 13.2% higher dose of erythropoiesis-stimulating agents.
Decreasing TSAT and higher ESA doses are associated with increasing platelet counts.
Folic acid treatment significantly improved hemoglobin levels and decreased epoetin alfa use.
Elemental iron requirement was reduced by half in patients receiving ferric citrate versus an active control.
These include use of lower ESA doses and hemoglobin levels.
Weekly dose of erythropoiesis-stimulating agents decreased and hemoglobin levels increased.
Patients with levels below 10 g/dL had the highest unadjusted mortality and all-cause hospitalization rates.
A transferrin saturation of 20% or less was associated with a 2.2 times increased risk of death from any cause.
Study also documents use of higher IV iron doses and declining hemoglobin levels.